Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TEVA PHARMACEUTICAL INDUSTRIES LTD

Get SEC filing alerts via email and in your feed for TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA TEVJF

TEVA PHARMACEUTICAL INDUSTRIES LTD

About TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries Limited is a global leader in generic and biosimilar medicines, innovative therapies, OTC products, and active pharmaceutical ingredients. Operating across multiple regions, it offers a broad portfolio in CNS, respiratory, oncology, and other therapeutic areas. The company leverages extensive R&D, manufacturing, and distribution capabilities to deliver high-quality, cost-effective medicines to patients worldwide. Its core focus is on innovation, portfolio optimization, and strategic growth.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TEVA PHARMACEUTICAL INDUSTRIES LTD

1
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports 2% Revenue Growth to $3.982 Billion in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports 4% Revenue Growth to $17.258 Billion in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports $4.48 Billion Revenue in Q3 2025, 3% Year-Over-Year Increase

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports Revenue Increase and Net Income Turnaround in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports $3.891 Billion Revenue in Q1 2025, 2% Year-Over-Year Increase

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports $16.544 Billion Revenue for 2024, Driven by Generic Sales

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports 13% Revenue Growth, Net Loss in Q3 2024 Due to Increased Legal Settlements and Goodwill Impairment

Via official filing (AI summary) | over 1 year ago | 0 comments